Related references
Note: Only part of the references are listed.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Niccolo Bolli et al.
LEUKEMIA (2018)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Silvana Konermann et al.
NATURE (2015)
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Nicolas Herranz et al.
NATURE CELL BIOLOGY (2015)
γ-Secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway
Jun-yang Li et al.
ACTA PHARMACOLOGICA SINICA (2014)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Understanding Biology to Tackle the Disease: Multiple Myeloma From Bench to Bedside, and Back
Giada Bianchi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction
Jin He et al.
CANCER RESEARCH (2012)
Survival of Cancer Stem Cells under Hypoxia and Serum Depletion via Decrease in PP2A Activity and Activation of p38-MAPKAPK2-Hsp27
Shih-Pei Lin et al.
PLOS ONE (2012)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
DR Carrasco et al.
CANCER CELL (2006)
Share Paper
